



Group 1642

Patent  
252/029

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re the Application of:

Catania, A.P., et. al.

Serial No.: 09/533,341

Filed: 3/23/2000

For: ANTIMICROBIAL AND ANTI-  
INFLAMMATORY PEPTIDES FOR USE IN  
HUMAN IMMUNODEFICIENCY VIRUS

Group Art Unit: 1642

Examiner: Not Yet Assigned

SEP 13 2000

TECH CENTER 1600/2900

TRANSMITTAL

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicant submits the following documents with this Transmittal Letter.

- (1) Information Disclosure Statement;
- (2) Form PTO-1449; and
- (3) References AA through BT.

LYON & LYON LLP

Dated: 9-5-00

By: Michael J. Wise  
Michael J. Wise  
Reg. No. 34.047

Library Tower  
633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(213) 489-1600

LA-153597.1

CERTIFICATE OF MAILING  
(37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

9-6-00  
Date of Deposit

SAMUEL TIL  
Name of Person Mailing Paper  
Samuel Til  
Signature of Person Mailing Paper



#5

Patent  
252/029

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Catania, A.P., et. al.

Serial No.: 09/533,341

Filed: 3/23/2000

For: ANTIMICROBIAL AND ANTI-  
INFLAMMATORY PEPTIDES FOR USE IN  
HUMAN IMMUNODEFICIENCY VIRUS

)  
) Group Art Unit: 1642  
)  
) Examiner: Not Yet Assigned  
)  
)  
)  
)  
)  
)  
)  
)  
)

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b)(3)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the its duty under 37 CFR § 1.56, Applicants submit the following information to the Examiner for consideration. In the attached form PTO-1449, Applicants list the submitted items with copies of the documents enclosed for the Examiner's convenience.

The items identified in this Information Disclosure Statement (IDS) may or may not be "material" pursuant to 37 CFR § 1.56 and Applicants' submission thereof shall not be construed as an admission that any such patent, publication, or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless Applicants specifically designate as such.

The filing of this IDS shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.


This IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of the

first office action. Thus, no petition or fee is required. If, however, Applicants' undersigned representative is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c) and is further authorized to charge any fee required by the filing of these papers to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,

LYON & LYON LLP

Dated: 9-5-00

By:   
Michael J. Wise  
Reg. No. 34,047

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(213) 489-1600

Enclosures: Form PTO-1449 with references attached  
Transmittal  
Postcard